We have also reported synergistic inhibitory efficacy achieved with our NB compounds and proteasome inhibitors in breast cancer and multiple myelomas [8, 9] and with CDK4/6 inhibitors in ER-positive breast cancer [8, 11, 46]. This evidence concerns the gene CDK4 and plasma cell myeloma.